Par Pharmaceutical

Since 1978, Par Pharmaceutical has been at the forefront of developing, manufacturing, marketing and distributing safe, innovative and cost-effective pharmaceuticals that help improve patient quality of life. Every week in America, several million Par prescriptions are dispensed. In return for the trust that is placed in us, we are committed to providing products of uncompromising quality. In fulfilling this mission, we deliver value to our customers and the physicians and patients that rely on us.

In September 2015, Endo International plc (NASDAQ: ENDP) (TSX: ENL) acquired Par Pharmaceutical, merging the business with Endo’s Qualitest, thereby expanding the generics business to a top five industry leader.

Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic and device products through its operating companies. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA.

Today, Par Pharmaceutical’s sales place it among the top 4 largest generic pharmaceutical companies in the United States. Par conducts manufacturing in the United States and abroad, and markets and/or licenses more than 200 prescription drug product families.

At Par, our most important resource is the talent and dedication of our more than 3,700 professionals, in offices in Chestnut Ridge, New York; Irvine, California; Rochester, Michigan; Stratford, Connecticut; Chennai, India; Montebello, New York; Huntsville, Alabama; and Charlotte, North Carolina. Each employee is part of a culture that values integrity, customer focus, teamwork, innovation and performance.

Since the beginning of 2015, Par has acquired Ethics Bio Lab Pvt Ltd, an Indiabased contract research organization that conducts bioavailability, bioequivalence, pharmacokinetic and clinical endpoint studies, and Innoteq, Inc., a developer and manufacturer of innovative-coated products, including orally dissolving thin films and transdermal patches. Par possesses one of the most promising new product pipelines in the generic drug industry, with more than 114 products awaiting FDA approval, including almost 35 first-to-files, and more than 300 other products in development. In recent years, the company has introduced generic versions of several major pharmaceutical products, including the following:

For more information, visit http://www.parpharm.com.